Scholars Central

ArticlePublished 2008

Long Term Survival on S-1 Monotherapy in a Patient with Recurrent Stage IV Pancreatic Cancer

Authors: Muhammad Wasif Saif, Susan Alsamarai, Chris Zergebel, Taro Furuie, Peter D Urrea, Joshua Zhang

Journal of the Pancreas

Volume 9 · Issue 2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Context Pancreatic cancer is the third most common gastrointestinal malignancy in the United States. Due to difficulty in diagnosis, 40% of patients are stage IV by the time of diagnosis and median survival is only four to six months. Current therapy for advanced pancreatic cancer focuses largely on gemcitabine. However, a relatively new drug, S-1, is showing promising results. Phase II studies of S-1 monotherapy and recent combination with gemcitabine were conducted for the treatment of metastatic pancreatic cancer. The early phase II study demonstrated a response rate approaching 20% while the combination is reaching more than 35%. Case report We report a 68-year-old man who presented with stage IIB pancreatic cancer which advanced to stage IV after undergoing a Whipple procedure and adjuvant treatment with gemcitabine. The patient was refractory to treatment with gemcitabine as well as irinotecan, taxotere, and cetuximab. He subsequently participated in a trial involving the drug S-1. He achieved 10- month survival with preserved quality of life: he had 14 cycles of S-1 and maintained an ECOG performance status of 0-1 throughout. Conclusion For this patient, 14 cycles of S-1 were well-tolerated for 10 months after failing two prior chemotherapeutic regimens suggesting important insight that S-1 may be active and convenient for its oral use and it may have favorable safety profile in patients with metastatic pancreatic cancer. Randomized trials are warranted to determine the effectiveness of S-1 for the treatment of pancreatic cancer.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of the Pancreas.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of the Pancreas
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Muhammad Wasif Saif”
  • BylineArticles whose byline prints “Susan Alsamarai”
  • BylineArticles whose byline prints “Chris Zergebel”
  • BylineArticles whose byline prints “Taro Furuie”
  • BylineArticles whose byline prints “Peter D Urrea”
  • BylineArticles whose byline prints “Joshua Zhang”